Shionogi And GSK Commence Phase I for Novel Antibiotics In Japan
This article was originally published in PharmAsia News
Executive Summary
Shionogi Co. Ltd and GlaxoSmithKline PLC will start Phase I study for novel cephem antibiotics targeting Gram-negative bacteria in Japan.